# EDGAR Filing Document

**Accession Number:** 0001412558
**File Stem:** 0001104659-25-107536
**Filing Date:** 2025-11
**Character Count:** 5732
**Document Hash:** c91046e6141e001a1884656b13830de0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-107536.hdr.sgml**: 20251106

**ACCESSION NUMBER**: 0001104659-25-107536

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251106

**FILED AS OF DATE**: 20251106

**DATE AS OF CHANGE**: 20251106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evotec SE
- **CENTRAL INDEX KEY:** 0001412558
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** 2M
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34041
- **FILM NUMBER:** 251456797

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** ESSENER BOGEN 7
- **CITY:** HAMBURG
- **PROVINCE COUNTRY:** 2M
- **ZIP:** 22419
- **BUSINESS PHONE:** 49-40-560-810

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** ESSENER BOGEN 7
- **CITY:** HAMBURG
- **PROVINCE COUNTRY:** 2M
- **ZIP:** 22419

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Evotec AG
- **DATE OF NAME CHANGE:** 20070917

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of November, 2025**

**COMMISSION FILE NUMBER 001-34041**

**Evotec SE**<br> (Translation of registrant's name into English)

**Essener Bogen 7**

**22419 Hamburg**

**Germany**

**Tel: +49 40 560810**<br> (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ◻

On November 06, 2025, Evotec SE (the "Company") resolved to implement a share repurchase program as described attached hereto as Exhibit 99.1.

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit** | **Description of Exhibit** |
| [99.1](tm2530472d1_ex99-1.htm) | [Announcement pursuant to Article 5(1)(a) of Regulation (EU) No. 596/2014 in conjunction with Article 2(1) of Delegated Regulation (EU) No. 2016/1052](tm2530472d1_ex99-1.htm) |

---

**SIGNATURE**

Pursuant to the requirements, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| **Evotec SE** | **Evotec SE** | **Evotec SE** |
| By: | /s/ Christian Wojczewski | /s/ Christian Wojczewski |
|  | Name: | Christian Wojczewski |
|  | Title: | Chief Executive Officer |

---

Date: November 06, 2025

## Exhibit 99.1

**Exhibit 99.1**

**Announcement pursuant to Article 5(1)(a) of Regulation (EU) No. 596/2014 in conjunction with Article 2(1) of Delegated Regulation (EU) No. 2016/1052**

Hamburg, 6 November 2025 – The management board of Evotec SE (Frankfurt Stock Exchange, ISIN: DE0005664809 and Nasdaq, ISIN: US30050E1055) resolved on 6 November 2025 to implement a share repurchase program.

During the period from 7 November 2025 until 17 December 2025, it is intended to acquire up to 290,000 Evotec shares at a total purchase price of up to EUR 3,000,000 excluding incidental acquisition costs. The acquisition will be effected exclusively via electronic trading on the Frankfurt Stock Exchange (Xetra).

The management board makes use of the authorization to acquire treasury shares as provided for in Section 71(1) No. 2 German Stock Corporation Act (AktG). The shares repurchased under the program shall, after their acquisition by the company, be converted into American Depositary Shares (ADS). These ADS shall be used exclusively to fulfil corresponding obligations under an employee share programme and shall be issued only to individuals who are or were employed by the company or an affiliated company.

The repurchase will be carried out in accordance with the safe harbour provisions of Article 5 of Regulation (EU) No. 596/2014 in conjunction with the provisions of Delegated Regulation (EU) No. 2016/1052 and in compliance with the requirements of Rule 10b5-1(c)(1)(i) paragraphs (A) and (B) under the U.S. Securities Exchange Act of 1934.

The repurchase will be carried out on behalf of Evotec SE by an independent credit institution. The credit institution makes its decisions on the timing of the acquisition of Evotec SE shares independently and uninfluenced by Evotec SE in accordance with Article 4(2)(b) of Delegated Regulation (EU) No. 2016/1052.

The share buyback will be carried out in accordance with the trading conditions set out in Article 3 of Delegated Regulation (EU) No. 2016/1052. The transactions related to the share repurchase program will be duly disclosed in a manner complying with the requirements of Article 5(3) of Regulation (EU) No. 596/2014 in conjunction with Article 2(2) and (3) of Delegated Regulation (EU) No. 2016/1052, no later than the end of the seventh trading day following their execution. Furthermore, Evotec SE will publish the disclosed transactions on the company's website at <u>www.evotec.com</u> in the section "Investor Relations & News" and ensure that the information remains publicly accessible for at least five years from the date of disclosure.

The Management Board of Evotec SE may terminate, suspend, and resume the share repurchase program at any time in compliance with applicable legal requirements.

Evotec SE

The Management Board